$2.35
-0.085-3.5%
Last update: Oct 14, 10:15 AM
$2.38
-0.05-2.06%

Altimmune (ALT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.13 | $-0.25 | $-0.25 | $-0.28 |
| Actual | $-0.12 | $-0.18 | $-0.27 | $-0.21 |
| Surprise | +7.69% | +28.0% | -8.00% | +25.0% |
| Revenue | ||||
| Estimate | $1400 | $1000 | $560 | $560 |
| Actual | $0 | $0 | $26000 | $5000 |
| Surprise | -100.0% | -100.0% | +4542.9% | +792.9% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.14 | $-0.16 | $-0.17 | $-0.17 |
| Revenue | ||||
| Consensus | $1400 | — | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $-0.12 | $-0.13 | 7.69 % |
| Q1 | May 13, 2026 | $-0.18 | $-0.25 | 28.0 % |
| Q4 | Mar 5, 2026 | $-0.27 | $-0.25 | -8.00 % |
| Q3 | Nov 6, 2025 | $-0.21 | $-0.28 | 25.0 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $0 | $1.40K | -100.0 % |
| Q1 | May 13, 2026 | $0 | $1.00K | -100.0 % |
| Q4 | Mar 5, 2026 | $26.00K | $560.00 | 4542.9 % |
| Q3 | Nov 6, 2025 | $5.00K | $560.00 | 792.9 % |